19th Jul 2019 13:21
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, July 19, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on July 17, 2019, Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 2000 Ordinary Shares at a price of GBP0.45 and 2000 American Depositary Shares (ADSs) at a price of USD2.59 per share. On July 18, 2019, Denise purchased 8000 Ordinary Shares at a price of GBP0.45 and 2000 ADSs at a price of USD2.55 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | Denise Scots-Knight
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 2000 Aggregated price: GBP0.45 | ||||
e) | Date of the transaction | 2019-07-17 | ||||
f) | Place of the transaction | AIMX | ||||
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | Denise Scots-Knight
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
| ||||
b) | Nature of the transaction | PURCHASE of ADSs | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 2000 Aggregated price: GBP2.59 | ||||
e) | Date of the transaction | 2019-7-17 | ||||
f) | Place of the transaction | XNMS | ||||
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | Denise Scots-Knight
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 8000 Aggregated price: GBP0.45 | ||||
e) | Date of the transaction | 2019-07-18 | ||||
f) | Place of the transaction | AIMX | ||||
1 | Details of the person discharging managerial responsibilities
| |||||
a) | Name | Denise Scots-Knight
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc
| ||||
b) | LEI | 213800U8JQHIJOS5AS09
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
| ||||
b) | Nature of the transaction | PURCHASE of ADSs | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 2000 Aggregated price: GBP2.55 | ||||
e) | Date of the transaction | 2019-7-18 | ||||
f) | Place of the transaction | XNMS | ||||
Related Shares:
MPH.L